CSPC Pharmaceutical (HKG:1093) said China's National Medical Products Administration approved clinical trials for its recombinant respiratory syncytial virus (RSV) vaccine candidate, SYS6057, according to a July 31 Hong Kong bourse filing.
The vaccine is intended to prevent lower respiratory tract disease caused by RSV in people aged 60 and older